重组噬菌体溶菌酶HY-133对金黄色葡萄球菌复合体的不同非洲克隆谱系（包括施氏葡萄球菌）具有体外活性。
The Recombinant Bacteriophage Endolysin HY-133 Exhibits In Vitro Activity against Different African Clonal Lineages of the Staphylococcus aureus Complex, Including Staphylococcus schweitzeri.
作者信息
Idelevich Evgeny A, Schaumburg Frieder, Knaack Dennis, Scherzinger Anna S, Mutter Wolfgang, Peters Georg, Peschel Andreas, Becker Karsten
机构信息
Institute of Medical Microbiology, University Hospital Münster, Münster, Germany.
Hyglos GmbH, Bernried, Germany.
出版信息
Antimicrob Agents Chemother. 2016 Mar 25;60(4):2551-3. doi: 10.1128/AAC.02859-15. Print 2016 Apr.
Abstract
HY-133 is a recombinant bacteriophage endolysin with bactericidal activity againstStaphylococcus aureus Here, HY-133 showedin vitroactivity against major African methicillin-susceptible and methicillin-resistantS. aureuslineages and ceftaroline/ceftobiprole- and borderline oxacillin-resistant isolates. HY-133 was also active againstStaphylococcus schweitzeri, a recently described species of theS. aureuscomplex. The activity of HY-133 on the tested isolates (MIC50, 0.25 μg/ml; MIC90, 0.5 μg/ml; range, 0.125 to 0.5 μg/ml) was independent of the species and strain background or antibiotic resistance.
摘要
HY-133是一种重组噬菌体溶菌酶，对金黄色葡萄球菌具有杀菌活性。在此，HY-133在体外对非洲主要的甲氧西林敏感和耐甲氧西林金黄色葡萄球菌谱系以及头孢洛林/头孢比普和临界耐苯唑西林分离株具有活性。HY-133对施氏葡萄球菌也有活性，施氏葡萄球菌是最近描述的金黄色葡萄球菌复合体中的一个物种。HY-133对测试分离株的活性（MIC50为0.25μg/ml；MIC90为0.5μg/ml；范围为0.125至0.5μg/ml）与物种、菌株背景或抗生素耐药性无关。
相似文献
1
The Recombinant Bacteriophage Endolysin HY-133 Exhibits In Vitro Activity against Different African Clonal Lineages of the Staphylococcus aureus Complex, Including Staphylococcus schweitzeri.
Antimicrob Agents Chemother. 2016 Mar 25;60(4):2551-3. doi: 10.1128/AAC.02859-15. Print 2016 Apr.
2
Bactericidal activity of bacteriophage endolysin HY-133 against Staphylococcus aureus in comparison to other antibiotics as determined by minimum bactericidal concentrations and time-kill analysis.
Diagn Microbiol Infect Dis. 2019 Apr;93(4):362-368. doi: 10.1016/j.diagmicrobio.2018.11.005. Epub 2018 Nov 20.
3
In vitro activity of ceftobiprole on 440 Staphylococcus aureus strains isolated from bronchopulmonary infections.
Med Mal Infect. 2017 Mar;47(2):152-157. doi: 10.1016/j.medmal.2016.10.004. Epub 2016 Nov 14.
4
Antimicrobial activity of ceftaroline and comparator agents tested against bacterial isolates causing skin and soft tissue infections and community-acquired respiratory tract infections isolated from the Asia-Pacific region and South Africa (2010).
Diagn Microbiol Infect Dis. 2013 May;76(1):61-8. doi: 10.1016/j.diagmicrobio.2013.01.005. Epub 2013 Mar 25.
5
The phage K lytic enzyme LysK and lysostaphin act synergistically to kill MRSA.
FEMS Microbiol Lett. 2008 Oct;287(2):185-91. doi: 10.1111/j.1574-6968.2008.01308.x. Epub 2008 Aug 21.
6
Activity of ceftobiprole against community-associated methicillin-resistant Staphylococcus aureus isolates recently recovered from US military trainees.
Diagn Microbiol Infect Dis. 2007 Dec;59(4):463-6. doi: 10.1016/j.diagmicrobio.2007.06.023. Epub 2007 Oct 29.
7
In vitro activity against Staphylococcus aureus of a novel antimicrobial agent, PRF-119, a recombinant chimeric bacteriophage endolysin.
Antimicrob Agents Chemother. 2011 Sep;55(9):4416-9. doi: 10.1128/AAC.00217-11. Epub 2011 Jul 11.
8
In vitro activity of ceftaroline against staphylococci from prosthetic joint infection.
Diagn Microbiol Infect Dis. 2016 Feb;84(2):141-3. doi: 10.1016/j.diagmicrobio.2015.10.012. Epub 2015 Oct 21.
9
Comparative in vitro activity of bacteriophage endolysin HY-133 against Staphylococcus aureus attached to vascular graft surface.
Med Microbiol Immunol. 2020 Feb;209(1):51-57. doi: 10.1007/s00430-019-00638-1. Epub 2019 Oct 17.
10
Lytic activity of recombinant bacteriophage phi11 and phi12 endolysins on whole cells and biofilms of Staphylococcus aureus.
Appl Environ Microbiol. 2007 Jan;73(1):347-52. doi: 10.1128/AEM.01616-06. Epub 2006 Nov 3.
引用本文的文献
1
[Phage endolysins-a novel class of antibacterial agents with a wide range of applications].
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2025 May 6. doi: 10.1007/s00103-025-04059-9.
2
Phage-Derived Endolysins Against Resistant Staphylococcus spp.: A Review of Features, Antibacterial Activities, and Recent Applications.
Infect Dis Ther. 2025 Jan;14(1):13-57. doi: 10.1007/s40121-024-01069-z. Epub 2024 Nov 16.
3
The Synergistic and Chimeric Mechanism of Bacteriophage Endolysins: Opportunities for Application in Biotherapeutics, Food, and Health Sectors.
Probiotics Antimicrob Proteins. 2025 Apr;17(2):807-831. doi: 10.1007/s12602-024-10394-1. Epub 2024 Nov 7.
4
Exploration of Bacterial Re-Growth as In Vitro Phenomenon Affecting Methods for Analysis of the Antimicrobial Activity of Chimeric Bacteriophage Endolysins.
Microorganisms. 2022 Feb 15;10(2):445. doi: 10.3390/microorganisms10020445.
5
Characterization of Clinical MRSA Isolates from Northern Spain and Assessment of Their Susceptibility to Phage-Derived Antimicrobials.
Antibiotics (Basel). 2020 Jul 25;9(8):447. doi: 10.3390/antibiotics9080447.
6
Comparative in vitro activity of bacteriophage endolysin HY-133 against Staphylococcus aureus attached to vascular graft surface.
Med Microbiol Immunol. 2020 Feb;209(1):51-57. doi: 10.1007/s00430-019-00638-1. Epub 2019 Oct 17.
7
In Vitro Activity of the Bacteriophage Endolysin HY-133 against Small-Colony Variants and Their Corresponding Wild Types.
Int J Mol Sci. 2019 Feb 7;20(3):716. doi: 10.3390/ijms20030716.
8
Phage Lysins for Fighting Bacterial Respiratory Infections: A New Generation of Antimicrobials.
Front Immunol. 2018 Oct 16;9:2252. doi: 10.3389/fimmu.2018.02252. eCollection 2018.
9
The Novel Phage-Derived Antimicrobial Agent HY-133 Is Active against Livestock-Associated Methicillin-Resistant Staphylococcus aureus.
Antimicrob Agents Chemother. 2018 Jun 26;62(7). doi: 10.1128/AAC.00385-18. Print 2018 Jul.
10
1st German Phage Symposium-Conference Report.
Viruses. 2018 Mar 29;10(4):158. doi: 10.3390/v10040158.
本文引用的文献
1
Missense mutations of PBP2a are associated with reduced susceptibility to ceftaroline and ceftobiprole in African MRSA.
J Antimicrob Chemother. 2016 Jan;71(1):41-4. doi: 10.1093/jac/dkv325. Epub 2015 Oct 5.
2
Staphylococcus aureus complex from animals and humans in three remote African regions.
Clin Microbiol Infect. 2015 Apr;21(4):345.e1-8. doi: 10.1016/j.cmi.2014.12.001. Epub 2014 Dec 11.
3
Novel staphylococcal species that form part of a Staphylococcus aureus-related complex: the non-pigmented Staphylococcus argenteus sp. nov. and the non-human primate-associated Staphylococcus schweitzeri sp. nov.
Int J Syst Evol Microbiol. 2015 Jan;65(Pt 1):15-22. doi: 10.1099/ijs.0.062752-0. Epub 2014 Sep 30.
4
New epidemiology of Staphylococcus aureus infection in Africa.
Clin Microbiol Infect. 2014 Jul;20(7):589-96. doi: 10.1111/1469-0691.12690. Epub 2014 Jul 12.
5
Population dynamics of Staphylococcus aureus from Northeastern Nigeria in 2007 and 2012.
Epidemiol Infect. 2014 Aug;142(8):1737-40. doi: 10.1017/S0950268813003117. Epub 2013 Dec 5.
6
Transmission of Staphylococcus aureus between mothers and infants in an African setting.
Clin Microbiol Infect. 2014 Jun;20(6):O390-6. doi: 10.1111/1469-0691.12417. Epub 2013 Nov 18.
7
MRSA in Africa: filling the global map of antimicrobial resistance.
PLoS One. 2013 Jul 29;8(7):e68024. doi: 10.1371/journal.pone.0068024. Print 2013.
8
Bacteriophage endolysins as novel antimicrobials.
Future Microbiol. 2012 Oct;7(10):1147-71. doi: 10.2217/fmb.12.97.
9
Drug-resistant human Staphylococcus aureus in sanctuary apes pose a threat to endangered wild ape populations.
Am J Primatol. 2012 Dec;74(12):1071-5. doi: 10.1002/ajp.22067. Epub 2012 Aug 21.
10
Epidemiology and population structure of Staphylococcus aureus in various population groups from a rural and semi urban area in Gabon, Central Africa.
Acta Trop. 2012 Oct;124(1):42-7. doi: 10.1016/j.actatropica.2012.06.005. Epub 2012 Jun 28.
Zotero 插件